Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

192 urolithiasis * vaccine

12th World AIDS Conference

- Keyword

Abstract -

n HIV-infected patients/ Urologic complaints in relation to indinavir
navir/Indinavir-induced urticaria and leukocytoclastic vasculitis; cr
tion/Nelfinavir-induced and successful desensitization/
ciated histoplasmosis in Uruguay /Clinical manifestation of AIDS-a
and settings/Effects of US-based HIV interventions on safer sex:
emic/Bridging the gap: NGOs and ASOs and the global
users (IDUs) along the US-Mexico border/The role of migration in
ve care services on the border/A trans-border case m

12372
60274
60967
22227
14283
44273
24103
34209

ted children/First large
evirapine interaction via
nning for HIV services/
ong young adults in the
sistance mutations in a
o drug treatment in six
ving regular care in the
or cryptococcosis in the
e tuberculosis patients,
n correctional facilities,
HIV/TB profiles from the
ositive persons in the
vention programs in the
women giving birth in a
projects (EIDPs) in the
/An assessment of the
d sexual behavior in the
V risk behaviors among
psychological health in
epidemics: Results of a
dicts HIV testing among
nic urban sample in the
artners in samples of
k, Hispanic, and White
ed care systems in the
ted persons at an urban
Africa compared to the
carinii pneumonia in the
I utilization practices of
kers in Houston, Texas,
atal transmission in the
ay/bisexual men in the
and 1997 in a cohort of
) enrolled in a high-risk
al sex workers from two
iderations from a 5 site
erpes virus type 8 in the
tiretroviral therapy in a
ng people of color in the
- Data from a national (
x by HIV-seronegative
uses female condoms/
crobicide in Mexico, the
positive MSMs in major
igh risk HIV-negative
drug treatment in three
Lessons learned from a
or HIV prevention in the
ns of condom efficacy in
HIV prevention efforts of
about their health care/
IV care program - The
HIV-1 urine EIA in three
+ persons in care in the
dwide internet access/
Ithcare coverage in the
se management in the
Ilection HIV tests in the
urients sampled at four
n a predominantly rural
of risk of HIV infection in
ds in HIV testing among
Ilection HIV tests in the
vention planning in the
al southern state in the
ansmission of HIV in the
evention planning in the
HIV care planning in the
ecommendations from
fordable/Expansion of
ces (CTS) for women in
or HIV? Results from a

US study of efficacy and tolerability of riton 173*/12246
prescriber education on dosing strategi 12396
federal strategies for increasing involve 12453
Army, 1985-1996: Current trends in an 518*/13212
military cohort of antiretroviral-naive re 13215
cities/Age-specific trends in seropreval 13224: Results from the HIV cost and services 13229: 1993-94 vs. 1996-97/Population-bas 13240,1993-1996/Characteristics of adult HI 13250,1993-1996/Characteristics of HIV-Inf 13265
and the UK derived from multiple survei 13268,1993-1996/Epidemiology of extrapul 13269
/Cost comparison of alternatively struct 13288
city/Explaining the decrease in HIV ser 13386: Linking HIV care and prevention servic 13444
substance abuse treatment system an 13586
population/HIV risk through drug use a 14103
youth/Eight-year trends in HIV risk beh 14110
young gay men/Self-acceptance of ga 154*/14135
multi-site rapid assessment and implic 14157
young gay men/Gay community integr 14189
/Culture counts: Understanding the con 14223
women/The effect of a theory-based HI 14274
women, age 18 to 25 years, 1986-199 14330
/Better short term self-reported health o 14345
Medical Center, 1991-1996/Tuberculo 22135
-Europe-Australia/Molecular and clini 22177
/Risk factors for pneumocystis carinii p 22183
physicians providing care to the HIV po 22222
/HIV risk factors among drug-using mal 23134: A population-based evaluation of prev 23282
/Social-normative factors partially expl 24*/23349
inner-city injection drug users (IDU)/Ini 23396
cohort/HIV risk behaviors among wom 23500
cities/Environmental factors in injectio 23535
study/Variation in patterns of methamp 24107
and Africa/Comparative prevalence of i 31189
inner city, advanced AIDS population. 32405: Federal efforts to ensure that HIV servi 32432
)survey of reproductive age women/Co 33106
gay/bisexual men at increased risk of H 33128
women at risk of HIV/STD: Who wants 33129, and Zimbabwe/Men's attitudes toward 33141
cities/Prevalence of antiviral medicatio 33169
populations/Oral chemoprophylaxis to 33193
metropolitan areas/Acquisition of steril 33197
vaccine preparedness study/Enabling 33215:Is there likely to be an impact?/STD co 525*/33238
national samples: Trends, predictors, a 33427
Catholic Social Service Agencies/Stre 34191
network of AIDS health fraud task force 34376
Ryan White CARE Act/Emerging care/ 34380
populations/Performance of calypte HI 41114
/Quality of medical care for three comm 42213
Public Health Service Expert Panel on 42292: Results from the chorus observational 42310
Department of Veterans Affairs/Inversi 443*/42429: Those who intended to use are not usi 43116
sites: Preliminary findings/HIV counsel 43117
southern state/The association of perc 43118
national samples: Trends, predictors, a 43122
adults, 1993 to 1996/Trends in HIV test 43127: Barriers and solutions/The use of hom 43133
to inform efforts in Argentina/Planning t 43177
/Factors influencing condom use amon 43320?/How common is secondary transmiss 43438
/Linking HIV care and prevention planni 43499
/New HIV planning challenges: Technic 43527
community-members likely to be target 43547
Medicaid system to cover HIV drugs wil 482*/44241
Government funded programs/Assess 44306
multisite sample/Are high-frequency a 60254

- Keyword Abstri
ary grades: A review of policy and evaluation practice/Recom
ching practices among women at high risk of HIV infection, Vac
HIV test: Data from the National Health Interview Survey/Rate
ree venue types in two cities/Sexual HIV transmission risk am
ome better than others/ bathhouses do HIV prevention: Some b
s from a representative sample/Disease stage distribution am
DS health planning: The Health Resources and Services Admini
and at-risk for HIV in six cities/Infrastructure of the service syst
man rights/AIDS in the: Still an exceptional disease needing ex
-infected persons in the USA /Higher rates of death with non-AIDSaly and Baltimore, MD, /Direct comparison of progression to
d patients in care in the: Who is missing out?/Underuse of pri
th men in seven cities, /HIV and predictors of unprotected re
n seven urban areas, /Prevalence and predictors of unprote
ong injectors in Seattle, /Drug treatment and HIV risk reductio
ts in the first year of life, /Implementation of recommendations
ng women in California,: 1998 through 1995/Trends in preval
ng women in California, /A population-based, door-to-door su
s risk of infection in the /Gender, power and HIV: The impact
ect in Washington, DC, /Permanency planning services for fa
ncy HIV Study (WIHS), /Prevalence of and risk factors for HH
mal blood donors from, India, Jamaica, Malaysia, and Thaila
n Francisco, California,, 1997-98/Receipt of protease inhibit
rtality: Chicago, Illinois, - 1996/Inequalities in declining HIV-r
National experience in,1993-1996/Allocating HIV preventio
ncy in Chicago, Illinois, /AIDS and the impact on life expectan
for Latinos in Maryland, /LUCES: An empowerment model for
ach of 30 patients from USAC, Abidjan/The Rorschach test and Al
he territory of the former USSR /Sero- and genotyping of HIV-1 vari
n HIV-1 transmission in utero /Placenta infection in HIV-1 transmis
ations in the CD4+ TCR V/i repertoire indicate fast progression to di
of T cell receptor (TCR) repertoire/Distinctive patterns of CD8 T
tabilization of the TCR repertoire and reduction of CD8+ T cell
encourage youth to get vaccinated against hepatitis B/How to enc
of economic incentives/ Vaccination among IDUs: The role of econ
replication by influenza vaccination (IV) in patients on potent antir
ovement of nucleic acid against HIV-1 toward strong s
g those with prior BCG or prior tuberculosis/Risk of
s participating in a HBV study. Extension of an ongoin
ents/Effect of influenza on viral loads in HIV patients/
ppropriate adjuvant for with HIV-1 derived multi-epito
xposure/Recombinant vaccine-induced protection against the hi
evaluation of Thai AIDS Vaccine Evaluation Group (TAVEG) in Th
ention Trials (HIVNET) Preparedness Study (VPS)/Feas
gh risk of HIV infection, Preparedness Study of HIVNET/
del for evaluation of HIV vaccine candidates/A new pathogenic SH
c T lymphocytes/DNA encoding an HIV epitope fused wit
with HIV infection/BCG effectiveness in preventing tuberc
V infection in hepatitis B cohorts in Amsterdam, New York
s for participation in HIV trials among men who have sex wi
g: Vital components in a trial preparation/HIV/AIDS risk be
with participation in HIV trials in Uganda/Perceived stigm
+ CTL induced in AIDS evaluation group phase I trials usi
Is epitopes/A polytope strategy for the co-delivery of mult
IV-1 DNA and avipox regimen/Protective T-cell mediat
n and fate of HIV-1 DNA in BALB/c mice/Tissue distributio
mbinant BCG-vectored against HIV-1 clade E strain/Con
nta-peptide conjugate on reduction of viral loads and HIV
ng route for HIV-1 DNA /Intranasal administration may be
ivalenet subtype B/E designed for Asia/Neutralizaion o
ficacy of pneumococcal (PV)/HIV-associated pneumonia
nogenicity of hepatitis B against in HIV seropositive adult p
s) in preparation for HIV efficacy trials/Recruitment of inje
enrolled in the HIVNET preparedness study/Retention of
nd preparation for HIV clinical trials in Belo Horizonte, Br
o prepare for large HIV trials in San Francisco/Asking for
binant gp160 envelope: contributions of host factors and v
munity cohorts for HIV-1 trials in northern Thailand; the Tha
ge/A recombinant BCG for HIV-1 protects cynomolgus mo
ss to participate in HIV trials in cohorts of young men havi
en to participate in HIV efficacy trials: Lessons learned fro
gag-pol facilitated DNA for HIV-1 prevention/AVEG 031:
ruction of a gp120 DNA /Determination of prevalent HIV-1

ontrolled phase I HIV-1 trial in Uganda/Recruitment of vol
se to HIV Thai E/MF59 administer of alone or combined w
th a combination HIV-1 regimen/CTL and neutralizing ant
Future planning for HIV evaluation of Thai AIDS Vaccine
gness to participate in a preparatory study in Rio de Janeir
nitiative/Videotape in a education initiative/Videotape in
ctiveness of hepatitis B in the HIV-infected patient/The eff

act
60335
60350
60354
60384
60385
60394
60633
60777
60899
13235
13332
22167
23120
23139
23223
171*/23269
23271
23458
23466
24209
31190
31192
42309
94*/43433
43510
60135
60865
24156
13205
23277
21104
212*/21106
109*/31121
33567
60276
21113
21205
22145
23169
32155
33224
548*/21200
33222
43543
60350
11228
11240
13263
13357
14148
14254
14278
495*/21192
21193
549*/21198
21203
21206
21209
21213
21214
22108
22327
23181
23447
23448
24215
31152
33212
33213
33214
33215
33216
33218

33219
33220
33221
33222
33337
33455
42405